Chronic obstructive pulmonary, COPD
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 40-75 years old; 2. Meet one of the following conditions: 1) FEV1/FVC =0.7 after application of bronchodilator; 3. Subjects must sign an informed consent form before participating in the study, and be able to participate in the study according to the plan and follow up for 5 years.
Exclusion criteria
Exclusion criteria: 1. Acute exacerbation in the past 3 months; 2. Suffer from other obvious lung tissue-destructive diseases, such as severe bronchiectasis and tuberculosis; 3. Suffer from severe pleural disease and/or sternum and rib disease; 4. Suffer from serious uncontrolled other system diseases; 5. Chest surgery or abdominal surgery in the past 3 months; 6. Eye surgery or retinal detachment in the past 3 months; 7. Myocardial infarction and/or hospitalization due to heart disease in the past 3 months; 8. ongoing anti-tuberculosis treatment; 9. During pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observe disease outcome and identify subgroups of COPD patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Identify risk factors for high-risk groups (GOLD 0) to progress to COPD;Times and severity of acute exacerbation of COPD during treatment;Blood immune indicators: Proteoglycan 4 (PRG4), C-reactive protein (CRP), serum amyloid A (SAA), procalcitonin (PCT), matrix metalloproteinases MMP-8, matrix metalloproteinases MMP -9;Pulmonary Surfactant Related Protein D (SP-D);Serum inflammatory factors: TNF-a, IL-8, IL-6, IL-2, GM-CSF;Induced sputum inflammation indicators: IL-1b, IL-8, IL-6, TNF-a, MPO and induced sputum cell count;PBMC, D-dimer (D-D), fibrinogen (FIB);Urinary Leukotriene B4 (LTB4);Exhaled nitric oxide (FeNO);Lung function test;CT scan;6-minute walk test; | — |
Countries
China
Contacts
The First Affiliated Hospital Of Guangzhou Medical University